<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7281209\results\search\testTrace\results.xml">
  <result pre="essential to intestinal immunity. In summary, RS inhibits influenza virus" exact="infection" post="and promotes antibody production, suggesting that RS is a"/>
  <result pre="production, suggesting that RS is a potential candidate for the" exact="treatment" post="of influenza virus infections. antiviral influenza virus rhamnan sulfate"/>
  <result pre="such as oseltamivir and zanamivir are often used for the" exact="treatment" post="of influenza virus infections. However, drug-resistant influenza strains have"/>
  <result pre="the characterization of the antiviral effects of RS against IFV" exact="infection" post="in vitro and in vivo. In addition, we show"/>
  <result pre="rhinovirus). The SI values of RS when added during viral" exact="infection" post="(Table 1A) were higher than the values obtained when"/>
  <result pre="than the values obtained when RS was added immediately after" exact="infection" post="(Table 1B) for all the enveloped viruses except for"/>
  <result pre="1, pretreating host cells for 3 h prior to viral" exact="infection" post="did not markedly inhibit IFV replication. In addition, no"/>
  <result pre="viral replication was observed when RS was added during virus" exact="infection" post="at 1 h, 3 h, or 6 h post-infection."/>
  <result pre="RS suppressed virus production most efficiently only when added during" exact="infection" post="for 1 h and at the same time of"/>
  <result pre="infection for 1 h and at the same time of" exact="infection" post="and throughout the subsequent incubation. These results of time-of-addition"/>
  <result pre="Immunocompetent and Immunocompromised Mice To show the effects of RS" exact="treatment" post="on immunocompetent and immunocompromised IFV-infected (2 Ã— 105 PFU/50"/>
  <result pre="(2 Ã— 105 PFU/50 Î¼L) mice (n = 16â€&quot;21 per" exact="treatment" post="group), we induced the immunocompromised state by frequent injections"/>
  <result pre="group (orally administered with water), the immunocompetent mice without 5-FU" exact="treatment" post="(5-FU (-) mice) and immunocompromised mice with 5-FU treatment"/>
  <result pre="5-FU treatment (5-FU (-) mice) and immunocompromised mice with 5-FU" exact="treatment" post="(5-FU (+) mice) showed approximately 20% and 30% reduction"/>
  <result pre="and 30% reduction in body weight, respectively, 8 days after" exact="infection" post="(Figure 3a,b). RS-treated mice with and without 5-FU treatment"/>
  <result pre="after infection (Figure 3a,b). RS-treated mice with and without 5-FU" exact="treatment" post="showed approximately 20% and 25% reduction in body weight,"/>
  <result pre="reduction of body weight from 7 to 9 days after" exact="infection" post="and had recovered by 11 days after infection. All"/>
  <result pre="fluids (BALFs) of the 5-FU (-) mice 3 days after" exact="infection" post="(Figure 4b and Figure S1b). Meanwhile, RS did not"/>
  <result pre="the BALFs of the 5-FU (+) mice 3 days after" exact="infection" post="(Figure 4b and Figure S1b). No virus was detected"/>
  <result pre="still be detected in the control mice 7 days after" exact="infection" post="(Figure 4 and Figure S1). In the 5-FU (+)"/>
  <result pre="antibodies in the sera at 7 and 14 days after" exact="infection" post="in both 5-FU (-) and FU (+) mice (Figure"/>
  <result pre="significantly suppressed antibody production at 3 and 7 days after" exact="infection" post="in FU (-) mice and at 7 and 14"/>
  <result pre="FU (-) mice and at 7 and 14 days after" exact="infection" post="in FU (+) mice. These results indicate that RS"/>
  <result pre="Furthermore, RS exhibited more potent antiviral activity when added before" exact="infection" post="than when added after infection. Through in vitro experiments,"/>
  <result pre="administration in vivo. A model to evaluate the effectiveness of" exact="treatment" post="and the prevention of IFV infection by the topical"/>
  <result pre="evaluate the effectiveness of treatment and the prevention of IFV" exact="infection" post="by the topical administration of RS may be designed"/>
  <result pre="this hypothesis. To analyze the effects of RS on IFV" exact="infection" post="in vivo, we performed IFV infection experiments in mice."/>
  <result pre="of RS on IFV infection in vivo, we performed IFV" exact="infection" post="experiments in mice. Our results showed that the oral"/>
  <result pre="shown in Figure 3b, progressive weight loss owing to virus" exact="infection" post="continued for a longer duration, and the recovery from"/>
  <result pre="virus production in the 5-FU-treated mice 3 days after virus" exact="infection" post="(Figure 4). RS treatment resulted in more rapid weight"/>
  <result pre="5-FU-treated mice 3 days after virus infection (Figure 4). RS" exact="treatment" post="resulted in more rapid weight recovery (Figure 3b) and"/>
  <result pre="shows that RS inhibits the early steps of influenza virus" exact="infection" post="and enhances neutralizing antibody production. RS is also able"/>
  <result pre="RS may be a potential tool for combatting influenza virus" exact="infection" post="and other enveloped viruses. Future studies may be conducted"/>
  <result pre="monolayers were incubated at 37 Â°C. Samples were added during" exact="infection" post="and throughout the incubation period or immediately after virus"/>
  <result pre="Agglutinin I (Vector Laboratories Inc., Burlingame, CA, USA) for the" exact="detection" post="of M cells. Then, the sections were counterstained with"/>
  <result pre="Studentâ€™s t-test. 5. Conclusions Here, we report that RS alleviates" exact="infection" post="by interfering with virus adsorption/internalization in vitro and by"/>
  <result pre="adsorption/internalization in vitro and by enhancing the antibody response against" exact="infection" post="in vivo, not at the stage of virus growth"/>
  <result pre="samples of mice taken 3 or 7 days after IFV" exact="infection" post="(relative values). LINK Click here for additional data file."/>
  <result pre="influenza A virus shedding in hospitalized patients and implications for" exact="infection" post="controlInfect. Control Hosp. Epidemiol.2007281071107610.1086/52010117932829 30.TreanorJ.J.HaydenF.G.VroomanP.S.BarbarashR.BettisR.RiffD.SinghS.KinnersleyN.WardP.MillsR.G.Efficacy and safety of the"/>
  <result pre="oral neuraminidase study groupJAMA20002831016102410.1001/jama.283.8.101610697061 31.MemoliM.J.AthotaR.ReedS.CzajkowskiL.BristolT.ProudfootK.HageyR.VoellJ.FiorentinoC.AdemposiA.et al.The natural history of influenza" exact="infection" post="in the severely immunocompromised vs nonimmunocompromised hostsClin. Infect. Dis.20145821422410.1093/cid/cit72524186906"/>
  <result pre="added to the culture medium 3 h prior to virus" exact="infection" post="(a), during infection for 1 h (b), during infection"/>
  <result pre="culture medium 3 h prior to virus infection (a), during" exact="infection" post="for 1 h (b), during infection for 1 h,"/>
  <result pre="virus infection (a), during infection for 1 h (b), during" exact="infection" post="for 1 h, and throughout the subsequent incubation (c),"/>
  <result pre="1 h, and throughout the subsequent incubation (c), immediately after" exact="infection" post="(d), at 1 h post-infection (p.i.) (e), at 3"/>
  <result pre="shown (n = 6â€&quot;11). Bodyweight on the day of viral" exact="infection" post="(0 d) was taken as 100%. Figure 4 Effects"/>
  <result pre="from independent duplicate assays. a Sample was added during viral" exact="infection" post="and throughout the subsequent incubation. b Sample was added"/>
 </snippets>
</snippetsTree>
